IBD Junior Analyst – Corporate Finance till Vator Securities
Som junior analytiker kommer fokus ligga på att assistera dina kollegor vid framtagandet av företagspresentationer, arbeta med research, samt bistå med administration kring transaktioner och projekt.
Teamet består idag av 9 personer och kommer att utökas med ytterligare juniora talanger.
Read More
Ett digitalt seminarium i samarbete med Hallvarsson & Halvarsson – 20 januari 2021
Vator Securities i samarbete med Hallvarsson & Halvarsson har nöjet att bjuda in till ett kostnadsfritt digitalt seminarium i hur ni kan arbeta proaktivt för att utbilda marknaden om er Equity Story, samt hur ni hanterar informationsgivningen i enlighet med börsregelverket och MAR.
Seminariet arrangeras onsdag den 20 januari 2021 mellan klockan 10:00-11:00.
Read More
Vator Securities advises SiB Solutions on 23 MSEK Private Placement
Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 23 million.
SiB Solutions offers a software for video content analytics that provides efficient monitoring and analysis of logistics processes to minimize shrinkage in the supply chain. The value of goods lost in logistics processes globally is estimated at around EUR 10 billion each month, with consequential costs of around EUR 20 billion.
Read More
Bolags- och kapitalmarknadsjurist till Vator Securities
Som bolags- och kapitalmarknadsjurist kommer du att arbeta med ECM-transaktioner där Vator Securities agerar finansiell rådgivare.
Din roll kommer vara att tillsammans med teamet inom Corporate Finance och ECM utarbeta optimala lösningar för en transaktion. Du kommer även att vara primär kontaktpunkt mot de externa legala rådgivarna i respektive transaktion.
Read More
Vator Securities rådger Xintela i 37 MSEK optionsinlösen
Vator Securities agerar som finansiell rådgivare i samband med transaktionen om SEK 37 miljoner.
Xintela är en innovatör i utvecklingen avregenerativa cellterapier och riktade cancerterapier baserade på denpatenterade markörteknologiplattformen XINMARK®.
Read More
Vator Securities advises NextCell Pharma on 150 MSEK Rights Issue
Vator Securities acts as Financial Adviser in connection with the transaction raising approximately SEK 150 million.
NextCell is a cell therapy company that has recently finished phase II with its leading drug candidate, ProTrans™, a treatment for type 1 diabetes. In the Company’s clinical trials, ProTrans™ has demonstrated both safety and efficacy regarding the patient’s own preservation of insulin production.
Read More
Vator Securities advises Scandion Oncology on 236 MSEK Rights Issue
Vator Securities acts as Financial Adviser in connection with the transaction raising approximately SEK 236 million.
Scandion Oncology is a clinical phase II biotechnology company addressing cancer drug resistance as a complement to existing anti-cancer therapies by developing first-in-class, oral add-on drugs. Used as a combination therapy, the Company’s products have the potential to quickly reach peak sales in addition to potentially offering better response rates and increased survival time with improved quality of life.
Read More
Closing the valuation gap driven by 90% likelihood of achieving US reimbursement – which is a license for medtechs to print money
We believe SciBase has built the necessary enablers to accelerate its topline growth and embark on a positive trajectory in the same direction as local peers such as Senzime and Redsense Medical. With a market value of SEK 200m in contrast to Senzime’s and Redsense Medical’s values of approximately SEK 1.3bn and SEK 660m, respectively, there are clearly numerous essentials with deep value in SciBase’s case that are being overlooked.
We initiate coverage with an Outperform rating and a target price of SEK 7.5, corresponding to an equity value of SEK 413m non diluted.
Read More